RT Journal Article
SR Electronic
T1 Variability in Urate-lowering Therapy Prescribing: A Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) Physician Survey
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP jrheum.200347
DO 10.3899/jrheum.200347
A1 Stamp, Lisa K.
A1 Taylor, William
A1 Gaffo, Angelo
YR 2020
UL http://www.jrheum.org/content/early/2020/09/28/jrheum.200347.abstract
AB Gout is common in people with chronic kidney disease (CKD) and its treatment is frequently suboptimal in this special population due to concerns over adverse events and/or efficacy of medications. There is controversy about the use of urate-lowering therapy (ULT) in those with CKD and lack of agreement about the dosing of allopurinol, the recommended first-line ULT1,2.